Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Shuch

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 TrialRobert J Motzer, Axel Bex, Paul Russo, et al.
Urologic Oncology|November 5, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meetingStephanie A Berg, Salvatore La Rosa, Tian Zhang, et al.
Future Oncology (London, England)|April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Iscience|July 25, 2022
Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancersRyosuke Jikuya, Koichi Murakami, Akira Nishiyama, et al.
Molecular Cancer Research : MCR|December 22, 2025
Genetically engineered human iPS cell-derived kidney organoid recapitulates an early stage of ALK fusion gene-associated renal tumorigenesisGo Noguchi, Masaya Baba, Shinji Ohtake, et al.
Ebiomedicine|May 14, 2023
Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinomaRyosuke Jikuya, Todd A Johnson, Kazuhiro Maejima, et al.
Nature Communications|November 24, 2025
Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancersRyosuke Jikuya, Todd A Johnson, Erika Muraoka, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 TrialRobert J Motzer, Axel Bex, Paul Russo, et al.
Urologic Oncology|November 5, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meetingStephanie A Berg, Salvatore La Rosa, Tian Zhang, et al.
Future Oncology (London, England)|April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
Iscience|July 25, 2022
Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancersRyosuke Jikuya, Koichi Murakami, Akira Nishiyama, et al.
Molecular Cancer Research : MCR|December 22, 2025
Genetically engineered human iPS cell-derived kidney organoid recapitulates an early stage of ALK fusion gene-associated renal tumorigenesisGo Noguchi, Masaya Baba, Shinji Ohtake, et al.
Ebiomedicine|May 14, 2023
Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinomaRyosuke Jikuya, Todd A Johnson, Kazuhiro Maejima, et al.
Nature Communications|November 24, 2025
Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancersRyosuke Jikuya, Todd A Johnson, Erika Muraoka, et al.
Pageof 4